Jackson Creek Investment Advisors LLC Buys Shares of 60,890 Indivior PLC $INDV

Jackson Creek Investment Advisors LLC purchased a new position in shares of Indivior PLC (NASDAQ:INDV) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 60,890 shares of the company’s stock, valued at approximately $1,468,000.

Other hedge funds have also recently modified their holdings of the company. Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new stake in Indivior in the second quarter valued at about $855,000. Pacer Advisors Inc. purchased a new position in shares of Indivior during the 3rd quarter worth approximately $9,086,000. Acadian Asset Management LLC boosted its stake in shares of Indivior by 124.4% in the second quarter. Acadian Asset Management LLC now owns 1,492,272 shares of the company’s stock valued at $21,977,000 after buying an additional 827,230 shares in the last quarter. Federated Hermes Inc. acquired a new position in Indivior during the third quarter worth $8,120,000. Finally, Geode Capital Management LLC lifted its holdings in Indivior by 1,122.6% in the second quarter. Geode Capital Management LLC now owns 1,576,915 shares of the company’s stock valued at $23,244,000 after acquiring an additional 1,447,939 shares during the period. 60.33% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Zacks Research cut shares of Indivior from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 13th. Northland Securities set a $50.00 price objective on Indivior in a research note on Tuesday, January 20th. Craig Hallum reaffirmed a “buy” rating and set a $41.00 price objective on shares of Indivior in a report on Friday, October 31st. HC Wainwright upped their target price on Indivior from $35.00 to $48.00 and gave the company a “buy” rating in a report on Monday, January 12th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Indivior in a report on Wednesday, January 28th. Five analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $39.33.

Insider Transactions at Indivior

In other news, Director Barbara Ryan purchased 775 shares of the stock in a transaction dated Monday, January 5th. The shares were bought at an average cost of $35.39 per share, for a total transaction of $27,427.25. Following the transaction, the director owned 1,963 shares in the company, valued at $69,470.57. This trade represents a 65.24% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director David E. Wheadon bought 1,771 shares of the stock in a transaction that occurred on Monday, January 5th. The shares were purchased at an average cost of $35.39 per share, for a total transaction of $62,675.69. Following the completion of the acquisition, the director owned 14,395 shares of the company’s stock, valued at $509,439.05. This trade represents a 14.03% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired 4,871 shares of company stock worth $172,385 over the last quarter.

Indivior Trading Down 1.1%

Indivior stock opened at $35.00 on Tuesday. The stock has a market cap of $4.38 billion, a P/E ratio of 38.04 and a beta of 0.80. Indivior PLC has a 52 week low of $7.62 and a 52 week high of $38.00. The stock has a 50 day moving average of $34.88 and a 200-day moving average of $28.14.

Indivior Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.